MilliporeSigma expands production capacities
2020 investments total more than US$400 million
BURLINGTON, Mass. — MilliporeSigma announced the broadening of its manufacturing footprint with a combined US$47 million investment at its production facilities in Danvers, Massachusetts, and Jaffrey, New Hampshire.
These expansions will increase capacity and output at these facilities in 2021 and 2022, respectively, and create nearly 700 new manufacturing positions.
“The global coronavirus pandemic has significantly increased demand for our single-use and virus filtration technologies, which we are supplying to more than 50 different companies working on Covid-19 vaccine candidates,” said Chris Ross, interim CEO, MilliporeSigma, in a prepared statement. “These investments will strengthen our global manufacturing footprint, allowing us to meet this unprecedented demand and help get lifesaving vaccines and therapies to more patients, faster.”
This expansion will add 65,000-square-feet of space to the Danvers single-use assembly operations, adding to the existing 120,000-square-foot facility. The total investment in Danvers is about US$25 million and will add approximately 400 jobs throughout 2021.
The Jaffrey expansion plans include adding 25,000 square feet to the existing 260,000-square-foot facility. The additional capacity includes new production lines and equipment to support the manufacturing of filtration devices and membrane products, specifically Durapore filters, Express filters, and the Viresolve product lines. The total investment in Jaffrey is about US$22 million. This expansion is expected to bring nearly 275 roles by 2022, once the expansion is completed.